Itraconazole in the treatment of New World mucocutaneous leishmaniasis

International Journal of Dermatology

Volumn 43, Issue 9, 2004, Pages 659-663

  Calvopina, Manuel ^{a,b,c,d,e,f,g}   Guevara, Angel G ^{a,b,c,d,e,f,g}   Armijos, Rodrigo X ^{a,b,c,d,e,f,g}   Hashiguchi, Yoshihisa ^{a,b,c,d,e,f,g}   Davidson, Robert N ^{a,b,c,d,e,f,g}   Cooper, Philip J ^{a,b,c,d,e,f,g}  

^a HOSPITAL VOZANDES   (Ecuador)

^b UNIVERSIDAD CENTRAL DEL ECUADOR   (Ecuador)

^c KOCHI MEDICAL SCHOOL   (Japan)

^d UNIVERSITY OF TEXAS AT EL PASO   (United States)

^e NORTHWICK PARK HOSPITAL   (United Kingdom)

^f Hospital Pedro Vicente Maldonado   (Ecuador)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; GAMMA INTERFERON; ITRACONAZOLE; MEGLUMINE ANTIMONATE; PAROMOMYCIN; PENTOXIFYLLINE;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ECUADOR; FEMALE; HUMAN; LIVER TOXICITY; MALE; NEPHROTOXICITY; OUTCOMES RESEARCH; RECURRENCE RISK; SIDE EFFECT; SKIN LEISHMANIASIS;

ADMINISTRATION, ORAL; ADULT; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; ITRACONAZOLE; LEISHMANIASIS, MUCOCUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 4644219747     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02183.x     Document Type: Article

References (27)

1. Osorio LE, Castillo CM, Ochoa MT. Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics. Am J Trop Med Hyg 1998; 59: 49-52.
2. Marsden PD, Badaro R, Netto EM, et al. Spontaneous clinical resolution without specific treatment in mucosal leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85: 221.
3. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80: 859-876.
4. Chance ML. New developments in the chemotherapy of leishmaniasis. Ann Trop Med Parasitol 1995; 89: S37-S43.
5. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharmaceut Design 2002; 8: 319-342.
6. Borelli D. A clinical trial of itraconazole in the treatment of deep mycosis and leishmaniasis. Rev Infect Dis 1987; 9: 57-63.
7. Dogra J, Saxena VN. Itraconazole and leishmaniasis: a randomised double blind trial in cutaneous disease. Int J Parasitol 1996; 26: 1413-1415.
8. Amato VS, Padilha ARS, Nicodemo AC, et al. Use of itraconazole in the treatment of mucocutaneous leishmaniasis: a pilot study. Int J Infect Dis 2000; 4: 153-157.
9. Calvopina M, Guevara AG, Armijos RX, et al. Clinical features of mucocutaneous leishmaniasis in the Amazonian Region of Ecuador. In: Hashiguchi Y, ed. Studies on New World Leishmaniasis and its Transmission, With Particular Reference to Ecuador. Kochi City: Kyowa Printing, 20001: 82-89.
10. Davies CR, Reithinger R, Campbell-Lendrum D, et al. The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica, Rio de Janeiro 2000; 16: 925-950.
11. Anonymous. Medical letter on drugs and therapeutics. Drugs Parasit Infect 2002; April: 1-12.
12. Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment of resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983; 77: 167-170.
13. Sampaio SA, Castro RM, Dillon NL, et al. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases. Int J Dermatol 1971; 10: 178-181.
14. Sampaio RNR, Marsden PD. Treatment of the mucosal form of leishmaniasis without response to glucantime with liposomal amphotericin B. Rev Soc Bras Med Trop 1997; 30: 125-128.
15. Amato VS, Nicodemo AC, Amato JG, et al. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemotber 2000; 46: 341-342.
16. Romero GA, Lessa HA, Macedo V, et al. Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (V.) braziliensis. Rev Soc Bras Med Trop 1996; 29: 557-565.
17. Llanos-Cuentas A, Echevarria J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for the treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997; 25: 677-684.
18. Falcoff E, Taranto NJ, Remondegui CE, et al. Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-γ and pentavalent antimony compounds. Trans R Soc Trop Med Hyg 1994; 88: 95-97.
19. Lessa HA, Machado P, Lima F, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001; 65: 87-89.
20. Badaro R, Lobo I, Nakatani M, et al. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report. Braz J Infect Dis 2001; 5: 223-232.
21. Rodriguez LV, Calderon VSW. Itraconazole en el tratamiento de la leishmaniasis tegumentaria Americana. Actual Terap Dermatol 1988; 1: 376-381.
22. Rodriguez LV, Dedet J-P, Paredes V, et al. A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 1995; 90: 525-528.
23. Croft SL, Yardley V, Kendrick H. Drug sensitivity of Leishmania species: some unresolved problems. Trans R Soc Trop Med Hyg 2002.; 96: S127-S129.
24. Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) vs ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 1165: 528-534.
25. Beach DH, Goad LJ, Holz GG Jr. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol 1988; 31: 149-162.
26. Chance ML, Goad LJ. In: Hide G, Mottram JC, Coombs GH, et al., eds. Trypanosomiasis and Leishmaniasis. Biology and Control. Wallingford: CAB International, 1997: 163-176.
27. Rangel H, Dagger F, Hernandez A, et al. Nourdly azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes. Antimicrob Agents Chemother 1996; 40: 2785-2791.